Pirenoxine
Systematic (IUPAC) name | |
---|---|
1,5-Dioxo-4H-pyrido[3,2-a]phenoxazine-3-carboxylic acid | |
Clinical data | |
Trade names | Catalin |
Identifiers | |
1043-21-6 | |
QS01XA91 | |
PubChem | CID 4846 |
ChemSpider | 4846 |
UNII | 27L0EP6IZK |
Chemical data | |
Formula | C16H8N2O5 |
308.24512 g/mol | |
SMILES
| |
|
Pirenoxine (abbreviated PRX, trade name Catalin) is a medication used in the possible treatment and prevention of cataracts. A report in the journal of Inorganic Chemistry showed that in liquid solutions pirenoxine could cause decreased cloudiness of a crystallin solution produced to mimic the environment of the eye. Pirenoxine interacts with selenite or calcium ions that have been proven as factors leading to the formation of lens cataract.[1]
Pirenoxine reduces the cloudiness of the lens solution containing calcium by 38% and reduced the cloudiness of the selenite solution by 11%.
References
- ↑ Liao, J. H.; Chen, C. S.; Hu, C. C.; Chen, W. T.; Wang, S. P.; Lin, I. L.; Huang, Y. H.; Tsai, M. H.; Wu, T. H.; Huang, F. Y.; Wu, S. H. (2011). "Ditopic Complexation of Selenite Anions or Calcium Cations by Pirenoxine: An Implication for Anti-Cataractogenesis". Inorganic Chemistry 50 (1): 365–377. doi:10.1021/ic102151p. PMID 21138325.